Table 1 Molecular, histological and clinical results from patients with splenic extramedullary hematopoiesis (EMH)

From: The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders

Case no.	BM diagnosis	JAK2 whole spleen	JAK2 EMH cells	JAK2 non-EMH cells	JAK2 BM	Spleen weight (g)	Histology pattern	Bcl-xL (%)
1	PV	M>W	—	—	—	1390	D	79
2	PV	M>W	—	—	—	5536	D	—
3	PV	M>W	—	—	—	3943	N	—
4	PV	M>W	—	—	—	1645	N	—
5^a	PV	M>W	—	—	M>W	2970	D	78
6^a	PV	M>W	—	—	W>M	3070	N	64
7^a	PV	W>M	—	—	M&W	4700	D	56
8	ET	W>M	W>M	W>M	—	285	D	35
9	CIMF	M>W	—	—	—	3500	D	81
10^a	CIMF	M>W	—	—	M>W	1700	D	52
11^a	CIMF	M>W	—	—	W	3332	D	82
12	CIMF	M&W	—	—	M>W	3000	D	—
13^a	CIMF-BC	M&W	—	—	M>W	2190	D	77
14	CIMF	M&W	M	M&W	—	2400	D	33
15	CIMF	W>M	M>W	W>M	—	960	D	—
16^a	CIMF	W>M	—	—	W>M	1400	D	82
17	CIMF	W>M	—	—	—	—	D	—
18	CIMF	W>M	—	—	—	3693	D	—
19	CIMF	W^b	M	W	—	1470	G	—
20	CIMF	W	—	—	—	3840	D	—
21^a	CIMF	W	—	—	W	2280	D	22
22	CIMF	W	W	W	—	2320	D	—
23^a	CIMF	W	—	—	W	820	D	30
24	CIMF	W	—	—	W	1233	N	—
25^a	CIMF-BC	W	—	—	W	885	D	34
26	CMPDu	M&W	M>W	M&W	—	2300	D	18
27	CMPDu	W	—	—	W	3850	D	—
28^a	CMPDu-BC	W	—	—	W	3900	D	31
29	CML	W	W	W	—	1405	D	34
30	CML	W	W	W	—	360	S	0
31	CML-BC	W	—	—	—	1880	G	0
32	CML	W	—	—	—	1510	N	—
33	CML	W	W	W	—	550	S	0
34^a	CMML	W>M	—	—	W>M	1390	D	72
35	CMML & fib	W	—	—	W	1319	—	—
36^a	CMML-BC	W	—	—	W	1099	D	41
37^a	CMML	W	—	—	W	2800	N	60
38^a	CMML	W	—	—	W	2250	D	9
39	MDSu	W>M	—	—	—	822	D	—
40	MDSu	W	—	—	—	1342	D	—
41	RAEB	W	—	—	W	170	D	44
42	AML	W	—	—	—	362	D	—
43	AML-MDS	W	—	—	—	1056	—	—
44	AML-CMML	W	—	—	—	3100	—	—
45	AML-CMPD	W	—	—	—	2040	D	—
46	AML-CMPD	W	—	—	—	3476	D	—
47	AML-CIMF	W	W	W	—	2100	D	47

Results from the 47 cases are shown. Diagnoses included PV (polycythaemia vera); ET (essential thrombocythaemia); CIMF (chronic idiopathic myelofibrosis); CIMF-BC (CIMF in blast crisis); CMPDu (chronic myeloproliferative disease, unclassified); CMPDu-BC (CMPDu in blast crisis); CML (chronic myeloid leukemia); CML-BC (CML in blast crisis); CMML (chronic myelomonocytic leukemia); MDSu (myelodysplastic syndrome, unclassified); RAEB (refractory anemia with excess blasts); AML (acute myeloid leukemia) and AML- (AML transformed from a preexisting condition). JAK2 genotype by real-time PCR melting curve analysis of EMH cells extracted from the whole spleen, splenic EMH cells enriched by laser capture microdissection, and splenic non-EMH cells enriched by laser capture microdissection is shown. Genotype is reported as M>W (predominately mutant allele detected via a dominant JAK2^V617F melting curve peak), M&W (equal amounts of mutant and wild-type allele detected via approximately equivalent peaks), and W>M (predominately wild-type allele detected via a dominant JAK2 wild-type peak) (Figure 1). Spleen weight is reported in grams (g). Histology pattern of EMH cells is reported as N (nodular), D (diffuse), G (granulocyte predominant) or S (scant). — indicates that an adequate specimen was not available for further analysis.
^aThe 15 cases also reviewed by different methodologies and different criteria as described in the Materials and methods section.
^bThat case 19 was considered to be JAK2^V617F positive for subsequent statistical analyses.

Back to article page

Table 1 Molecular, histological and clinical results from patients with splenic extramedullary hematopoiesis (EMH)

Search

Quick links